SOCIETAL PREFERENCES FOR MENINGOCOCCAL B VACCINATION IN CHILDREN: A DISCRETE-CHOICE EXPERIMENT IN SPAIN

F. Martinón-Torres, Á. Gil de Miguel, J. Ruiz-Contreras, L.A. Vallejo-Aparicio, A. García, M.C. Gonzalez-Inchausti, E. de Gomensoro, Z. Kocaata, C. Gabás-Rivera, M. Comellas, M. Prades, L. Lizán



Neisseria meningitidis serogroup B (MenB) is the most common cause of bacterial meningitis in many industrialized countries.




Most cases occur in children, with infants less than 1 year of age being the most frequently affected.



It can be effectively prevented by vaccination.

In absence of a National Immunization Program in Spain, the risk-benefit and financial impact of immunizing children against MenB needs to be weighted.



SIX ATTRIBUTES

- Age of protection Cost
- **Duration of protection**
- Percentage of protection
 - Adverse events
 - Expert/Authority recommendations

WHAT PARENTS AND PAEDIATRICIANS VALUE MOST Recommendation Recommendation 26.1% 23.7% Age 22.6% Cost 26.4% % Protection % Protection 22.9% 27.2% **Parents Paediatricians** 26.4% Cost 7.8% Expert/authority 26.1% 23.7% recommendation % Protection 22.9% 27.2% Age of protection 7.3% 22.6%

Expert recommendation and percentage of protection were essential attributes for both groups.

Considering the preferences of key social segments is critical when including new vaccines in National Immunization Programs.

*This methodology, aimed here at assessing individual preferences for MenB vaccine, is based on the premise that medical interventions can be described as combinations of different attributes

